Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction.
OBJECTIVE
To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction.


METHODS
A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients.


RESULTS
The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01).


CONCLUSIONS
A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.
Department of Urology, Mersin Toros State Hospital, Mersin, Turkey.
Mehmet
M
Karabakan
Department of Urology, Mengucek Gazi Research and Training Hospital, Erzincan University, Erzincan, Turkey.
Ercument
E
Keskin
Department of Urology, Faculty of Medicine, Izmir University, Izmir, Turkey.
Serkan
S
Akdemir
Department of Urology, Mengucek Gazi Research and Training Hospital, Erzincan University, Erzincan, Turkey.
Aliseydi
A
Bozkurt
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D004542:Ejaculation / Q000187:drug effects* / Q000502:physiology; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects* / Q000502:physiology; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D061686:Premature Ejaculation / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D000068581:Tadalafil / Q000008:administration & dosage*; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
D001786:Blood Glucose; D058986:Phosphodiesterase 5 Inhibitors; D013739:Testosterone; D000068581:Tadalafil; D002784:Cholesterol
Ejaculation; Erectile Dysfunction; Tadalafil